DRNA Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 01:00):

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals...

Stats
Tagesvolumen	5.54M
Durchschnittsvolumen	3.03M
Marktkapitalisierung	0.00
EPS	$-0.220 ( 2021-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.989 (2.59%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-28	Koppel Adam	Sell	3 080 237	Common Stock
2021-12-28	Koppel Adam	Sell	3 333	Restricted Stock Units
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)
2021-12-28	Koppel Adam	Sell	25 000	Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 12 087 \| Sell: 8 528 928

Volumen Korrelation

Lang: 0.55 (weak)

Kurz: 0.93 (very strong)

Signal:(82.281) Expect same movement, but be aware

Dicerna Pharmaceuticals Korrelation

10 Am meisten positiv korreliert
ORTX	0.976
ASLN	0.972
ADMS	0.97
CSII	0.969
GRBK	0.962
WPRT	0.96
UNCY	0.959
NERV	0.959
NATI	0.958
NNOX	0.956

10 Am meisten negativ korreliert
CPTN	-0.96
AADI	-0.958
CARA	-0.957
STIM	-0.956
PRAA	-0.955
BRKL	-0.953
VEON	-0.948
PEBK	-0.947
TCPC	-0.947
MDRX	-0.946

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Dicerna Pharmaceuticals Korrelation - Währung/Rohstoff

0.21
( neutral )

0.70
( moderate )

0.36
( neutral )

0.60
( weak )

-0.87
( strong negative )

-0.24
( neutral )

Dicerna Pharmaceuticals Finanzdaten

Annual	2020
Umsatz:	$164.31M
Bruttogewinn:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2020
Umsatz:	$164.31M
Bruttogewinn:	$164.31M (100.00 %)
EPS:	$-1.520

FY	2019
Umsatz:	$23.90M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.760

FY	2018
Umsatz:	$6.18M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.600

Financial Reports:

No articles found.

Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.